Subscribe
12 December 2017Big Pharma

Teva drops Copaxone generic suit against Mylan

Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva suffers defeat as Copaxone claims invalidated
27 October 2017   The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.
Americas
Teva sues Mylan over Copaxone patent infringement
18 January 2017   Teva has sued Mylan for alleged patent infringement over Copaxone, a treatment for patients with relapsing-remitting forms of multiple sclerosis.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Teva suffers defeat as Copaxone claims invalidated
27 October 2017   The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.
Americas
Teva sues Mylan over Copaxone patent infringement
18 January 2017   Teva has sued Mylan for alleged patent infringement over Copaxone, a treatment for patients with relapsing-remitting forms of multiple sclerosis.

More on this story

Big Pharma
Teva suffers defeat as Copaxone claims invalidated
27 October 2017   The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.
Americas
Teva sues Mylan over Copaxone patent infringement
18 January 2017   Teva has sued Mylan for alleged patent infringement over Copaxone, a treatment for patients with relapsing-remitting forms of multiple sclerosis.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility